{"id":44037,"date":"2025-10-21T21:39:52","date_gmt":"2025-10-21T13:39:52","guid":{"rendered":"https:\/\/flcube.com\/?p=44037"},"modified":"2025-10-21T21:39:53","modified_gmt":"2025-10-21T13:39:53","slug":"novo-nordisk-secures-fda-approval-for-rybelsus-to-reduce-cardiovascular-risk-in-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44037","title":{"rendered":"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes"},"content":{"rendered":"\n<p><strong>Novo Nordisk (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>)<\/strong> announced that the U.S. Food and Drug Administration (FDA) has granted a new indication for <strong>Rybelsus<\/strong>, the company\u2019s oral GLP\u20111 agonist semaglutide. The approval expands Rybelsus 7\u202fmg and 14\u202fmg dosage forms to lower the risk of major adverse cardiovascular events (MACE) \u2014 including cardiovascular death, heart attack, and stroke \u2014 in adults with type\u202f2 diabetes who are at high cardiovascular risk, irrespective of prior events.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\"><strong>Key Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First Oral GLP\u20111 Therapy<\/strong> \u2013 Rybelsus remains the only oral GLP\u20111 agonist available worldwide.<\/li>\n\n\n\n<li><strong>Expanded Indication<\/strong> \u2013 Both 7\u202fmg and 14\u202fmg tablets now authorized for primary and secondary cardiovascular prevention in type\u202f2 diabetes.<\/li>\n\n\n\n<li><strong>Clinical Proof<\/strong> \u2013 Data from the Phase\u202fIII <strong>SOUL<\/strong> trial showed a 14\u202f% relative risk reduction in MACE with 14\u202fmg Rybelsus versus placebo, on top of standard care.<\/li>\n\n\n\n<li><strong>Market Position<\/strong> \u2013 Rybelsus first approved in 2019 for glycaemic control; elevated to a first\u2011line option in 2023.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-patients-and-clinicians\"><strong>Implications for Patients and Clinicians<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Broadening Therapeutic Options<\/strong> \u2013 Enables clinicians to prescribe an oral, once\u2011daily medication that addresses both glucose control and cardiovascular risk.<\/li>\n\n\n\n<li><strong>High\u2011Risk Population Coverage<\/strong> \u2013 The indication applies to patients with or without prior cardiovascular events, addressing a large unmet need.<\/li>\n\n\n\n<li><strong>Patient Adherence<\/strong> \u2013 Oral formulation may improve adherence compared to injectables, potentially translating into better real\u2011world outcomes.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44038,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[69,39,148,865,15],"class_list":["post-44037","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cvd","tag-diabetes","tag-novo-nordisk","tag-nyse-nvs","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted a new indication for Rybelsus, the company\u2019s oral GLP\u20111 agonist semaglutide. The approval expands Rybelsus 7\u202fmg and 14\u202fmg dosage forms to lower the risk of major adverse cardiovascular events (MACE) \u2014 including cardiovascular death, heart attack, and stroke \u2014 in adults with type\u202f2 diabetes who are at high cardiovascular risk, irrespective of prior events.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44037\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted a new indication for Rybelsus, the company\u2019s oral GLP\u20111 agonist semaglutide. The approval expands Rybelsus 7\u202fmg and 14\u202fmg dosage forms to lower the risk of major adverse cardiovascular events (MACE) \u2014 including cardiovascular death, heart attack, and stroke \u2014 in adults with type\u202f2 diabetes who are at high cardiovascular risk, irrespective of prior events.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44037\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T13:39:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-21T13:39:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2112.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes\",\"datePublished\":\"2025-10-21T13:39:52+00:00\",\"dateModified\":\"2025-10-21T13:39:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037\"},\"wordCount\":243,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2112.webp\",\"keywords\":[\"CVD\",\"Diabetes\",\"Novo Nordisk\",\"NYSE: NVS\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44037#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44037\",\"name\":\"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2112.webp\",\"datePublished\":\"2025-10-21T13:39:52+00:00\",\"dateModified\":\"2025-10-21T13:39:53+00:00\",\"description\":\"Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted a new indication for Rybelsus, the company\u2019s oral GLP\u20111 agonist semaglutide. The approval expands Rybelsus 7\u202fmg and 14\u202fmg dosage forms to lower the risk of major adverse cardiovascular events (MACE) \u2014 including cardiovascular death, heart attack, and stroke \u2014 in adults with type\u202f2 diabetes who are at high cardiovascular risk, irrespective of prior events.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44037\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2112.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2112.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44037#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted a new indication for Rybelsus, the company\u2019s oral GLP\u20111 agonist semaglutide. The approval expands Rybelsus 7\u202fmg and 14\u202fmg dosage forms to lower the risk of major adverse cardiovascular events (MACE) \u2014 including cardiovascular death, heart attack, and stroke \u2014 in adults with type\u202f2 diabetes who are at high cardiovascular risk, irrespective of prior events.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44037","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes","og_description":"Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted a new indication for Rybelsus, the company\u2019s oral GLP\u20111 agonist semaglutide. The approval expands Rybelsus 7\u202fmg and 14\u202fmg dosage forms to lower the risk of major adverse cardiovascular events (MACE) \u2014 including cardiovascular death, heart attack, and stroke \u2014 in adults with type\u202f2 diabetes who are at high cardiovascular risk, irrespective of prior events.","og_url":"https:\/\/flcube.com\/?p=44037","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-21T13:39:52+00:00","article_modified_time":"2025-10-21T13:39:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2112.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44037#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44037"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes","datePublished":"2025-10-21T13:39:52+00:00","dateModified":"2025-10-21T13:39:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44037"},"wordCount":243,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44037#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2112.webp","keywords":["CVD","Diabetes","Novo Nordisk","NYSE: NVS","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44037#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44037","url":"https:\/\/flcube.com\/?p=44037","name":"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44037#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44037#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2112.webp","datePublished":"2025-10-21T13:39:52+00:00","dateModified":"2025-10-21T13:39:53+00:00","description":"Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted a new indication for Rybelsus, the company\u2019s oral GLP\u20111 agonist semaglutide. The approval expands Rybelsus 7\u202fmg and 14\u202fmg dosage forms to lower the risk of major adverse cardiovascular events (MACE) \u2014 including cardiovascular death, heart attack, and stroke \u2014 in adults with type\u202f2 diabetes who are at high cardiovascular risk, irrespective of prior events.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44037#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44037"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44037#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2112.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2112.webp","width":1080,"height":608,"caption":"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44037#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type\u202f2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2112.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44037"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44037\/revisions"}],"predecessor-version":[{"id":44039,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44037\/revisions\/44039"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44038"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}